Livogiva is a medicine used for the treatment of osteoporosis (a disease that makes bones fragile) in: - women who have been through the menopause; - men who are at an increased risk of fractures; - men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid). Livogiva is a ‘biosimilar medicine’. This means that Livogiva is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Livogiva is Forsteo. Livogiva contains the active substance teriparatide.
Therapeutic Indication
### Therapeutic indication Livogiva is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Therapeutic Area (MeSH)
N/AATC Code
H05AA02
ATC Item
teriparatide
Pharmacotherapeutic Group
Calcium homeostasis
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| teriparatide | N/A | 特立帕肽 |
EMA Name
Livogiva
Medicine Name
Livogiva
Aliases
N/ANo risk management plan link.
